Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Dacogen · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| All patients | EXPERIMENTAL | All participants enrolled. |
| Name | Type | Description |
|---|---|---|
| Dacogen™ (decitabine) | DRUG | Dacogen™ (decitabine) is a FDA approved drug (NDA - 021790) for the treatment of myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia). Decitabine will be given on this study at 45 mg/m2 IV over 2 hrs |
| Vectibix® (panitumumab) | DRUG | Vectibix® (panitumumab) is a FDA approved drug (BLA-125147) indicated as a single agent for the treatment of EGFR-expressing metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine, oxaliplatin, and irinotecan chemotherapy regimens. Approval is based on progression-free survival; no data demonstrate an improvement in disease-related symptoms or increased survival. DRUG DESCRIPTION Vectibix® (panitumumab) is a recombinant, human IgG2 kappa monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). Panitumumab has an approximate molecular weight of 147 kDa. Panitumumab is produced in genetically engineered mammalian (Chinese Hamster Ovary) cells. Panitumumab will be given on this study at 6 mg/kg, IV over 1 hr |
Inclusion Criteria: 1. At least third line stage IV metastatic colorectal cancer or metastatic colorectal cancer patients intolerant to second line therapy. 2. Tumor is KRAS wild-type. 3. ECOG performance status of 0-1 4. Age (≥)18 5. Adequate bone marrow function (ANC \>1500/mm3, hemoglobin \>9 g/...
Top 20 of 77 competitors
Dacogen is a small molecule being studied for the treatment of colorectal cancer. It is currently in Phase 1 clinical development as an investigational therapy. The drug has been evaluated in a completed clinical trial involving patients with KRAS wild-type metastatic colorectal cancer.
Dacogen is being developed by Amgen Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol AMGN. The drug is currently in Phase 1 clinical development for the treatment of colorectal cancer.
Dacogen is currently in Phase 1 clinical development. It is an investigational drug being studied for the treatment of colorectal cancer. The drug has completed one Phase 1 clinical trial, and it is not yet approved by regulatory authorities.
Dacogen has been studied in one completed clinical trial with the identifier NCT00879385, titled "KRAS Wild-type Metastatic Colorectal Cancer Trial." This Phase 1 trial enrolled 21 participants in the United States and included patients aged 18 years and older with colorectal cancer.
Dacogen is the brand name for decitabine, a small molecule drug. In the context of this development program, it is being investigated for use in colorectal cancer. The drug is currently in Phase 1 clinical development by Amgen Inc.